FMP
Enter
API Tools
Extras
Harmony Biosciences Holdings, Inc.
HRMY
NASDAQ
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is based in Plymouth Meeting, Pennsylvania.
32.72 USD
0 (0%)
WACOC
Price
36.75
Beta
Diluted Shares Outstanding
45M
Costof Debt
4.09
Tax Rate
After Tax Cost Of Debt
4.09
Risk Free Rate
Market Risk Premium
Cost Of Equity
Total Debt
2.04B
Total Equity
1.65B
Total Capital
3.69B
Debt Weighting
55.2
Equity Weighting
44.8
Wacc
5.59
